Previous Page
11-11/12 :: November/December 2011
nanotimes
Companies Facts
and Kazakhstan. The LOI includes Delrus‘ financial and professional support for the regulatory approval of NanoTherm®
therapy in brain tumors and other
indications in Russia, including pancreatic and pro- state cancer.
“I am extremely pleased that we are working toge- ther with Delrus to establish a comprehensive colla- boration to distribute NanoTherm®
and Kazakhstan,” said Dr. Andreas Jordan, Founder and member of the Executive Board at MagForce. “Their experience and excellent track record open up significant opportunities for MagForce in Central and Eastern European markets.”
icronit is proud to present its newly launched MEMS division. This division is specialised in
the design, prototyping and manufacturing of MEMS products and wafers based on glass.
Micronit is specialised in the manufacturing of micro- fluidic lab-on-a-chip products and has over 10 years experience in all kinds of micromachining technolo- gies; mainly in glass but also in other materials such as silicon and polymers. The Micronit manufactu- ring line is capable of processing several hundreds of thousands of wafers per year in various substrate sizes (100mm to 300mm).
anoCarrier Co., Ltd. (TSE: 4571) and LFB Biotechnologies (LFB) have agreed to enter
N
anocomp Technologies, Inc., a developer of performance materials and component pro-
ducts from carbon nanotubes (CNTs), has been selected by the United States Government, under the Defense Production Act Title III program (“DPA Title III”), to supply CNT yarn and sheet material for the program needs of the Department of Defense, as well as to create a path toward commercialization for civilian industrial use. Nanocomp’s CNT yarn and sheet materials are currently featured within the ad- vanced design programs of several critical DoD and NASA applications.
“To maintain a competitive edge in defense, there is an urgent need for a new generation of multifunc- tional materials to improve combat systems in space, air, ground and sea,” said Peter Antoinette, presi- dent and CEO of Nanocomp Technologies. “We are extremely proud that our CNT material can deliver these strategic advantages and our efforts now turn to
therapy in Russia
into a new Research Collaboration Agreement, in which a new study, including that for a long-term safety, shall be undertaken to further assess the long term safety of a sustained release drug product using NanoCarrier’s Micellar Nanoparticle Techno- logy applied to LFB’s recombinant human blood coagulation Factor VIIa (rhFVIIa) for the therapeutic treatment of hemophilia. The purpose of this new study is to provide NanoCarrier and LFB with re- levant long-term safety as well as efficacy data in addition to the basic pharmacological and safety data of the sustained release drug product using NanoCarrier’s Micellar Nanoparticle Technology.
23